<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Carvedilol: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Carvedilol: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Carvedilol: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9208" href="/d/html/9208.html" rel="external">see "Carvedilol: Drug information"</a> and <a class="drug drug_patient" data-topicid="11802" href="/d/html/11802.html" rel="external">see "Carvedilol: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F146697"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Coreg;</li>
<li>Coreg CR</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866210"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Carvedilol;</li>
<li>Auro-Carvedilol;</li>
<li>JAMP-Carvedilol;</li>
<li>PMS-Carvedilol;</li>
<li>TEVA-Carvedilol</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1051516"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antihypertensive Agent</span>;</li>
<li>
<span class="list-set-name">Beta-Adrenergic Blocker, Nonselective With Alpha-Blocking Activity</span></li></ul></div>
<div class="block dop drugH1Div" id="F52812489"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Individualize dosage for each patient; monitor patients closely during initiation and upwards titration of dose; reduce dose for hypotension or bradycardia. Pharmacokinetic data suggest a faster carvedilol elimination in young pediatric patients (&lt;3.5 years of age), which may require more frequent dosing (3 times daily) and a higher target dose per kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12040358','lexi-content-ref-17848651']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12040358','lexi-content-ref-17848651'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="86fd017b-f098-427e-b843-c16a24638f11">Heart failure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure: Note:</b> Prior to initiating therapy, other congestive heart failure medications should be stabilized and fluid retention minimized.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Limited data available, reported regimens and efficacy results variable; optimal dose not established:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: Oral: Initial: 0.04 to 0.075 mg/kg/dose twice daily titrate as tolerated; may increase dose by 50% to 100% every 2 weeks; maximum daily dose: 1 mg/kg/<b>day</b> up to 50 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11295713','lexi-content-ref-23108482','lexi-content-ref-15261177','lexi-content-ref-17848651']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11295713','lexi-content-ref-23108482','lexi-content-ref-15261177','lexi-content-ref-17848651'])">Ref</a></span>). Dosing based on 2 retrospective analyses and 1 prospective, randomized-controlled study (n=110, age range: 3 months to 19 years) which showed improvement in left ventricular function and heart failure symptoms. However, a large, multicenter, double-blind, placebo-controlled, dose-finding trial was not able to show statistical difference in treatment effect compared to placebo; of note, a subset analysis suggested ventricular morphology may play a role in the efficacy of carvedilol in the treatment of heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17848651']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17848651'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52729628"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Mild to severe impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; in adults, no adjustment is necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10424319','lexi-content-ref-1505616','lexi-content-ref-7681374']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10424319','lexi-content-ref-1505616','lexi-content-ref-7681374'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: Hemodialysis does not appear to significantly clear carvedilol.</p></div>
<div class="block dohp drugH1Div" id="F52729629"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling. In adults, use is contraindicated.</p></div>
<div class="block doa drugH1Div" id="F146702"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9208" href="/d/html/9208.html" rel="external">see "Carvedilol: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="13bd6bb4-812a-4adb-9d1b-a07b36a7a601">Angina, chronic stable</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Angina, chronic stable (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For vasospastic angina, beta-blockers are not recommended; other agents (eg, calcium channel blockers, nitrates) are preferred. For nonvasospastic angina, guidelines recommend titrating dose to a resting heart rate of 55 to 60 beats per minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23166211']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23166211'])">Ref</a></span>), while other experts recommend a target of 60 to 70 beats per minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kannam.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kannam.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Immediate release: Oral:</b> Initial: 12.5 mg twice daily; increase dose as tolerated to desired effect; usual dosage range: 25 to 50 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9174677','lexi-content-ref-9794346']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9174677','lexi-content-ref-9794346'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6086960c-10cb-4421-ba68-b5977a0bab8c">Atrial fibrillation/flutter, maintenance of ventricular rate control</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atrial fibrillation/flutter, maintenance of ventricular rate control</b>
<b> (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Initiate cautiously in patients with concomitant heart failure. Avoid initiating or up-titrating therapy in patients with decompensated heart failure; for unstable patients, electrical cardioversion is preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24682347','lexi-content-ref-33081529']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24682347','lexi-content-ref-33081529'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Immediate release: Oral:</b> Initial: 3.125 mg twice daily; increase dose as tolerated to achieve ventricular rate control up to 25 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24682347']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24682347'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b43376ec-cceb-40f9-ad1e-9137f312af09">Heart failure with reduced ejection fraction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure with reduced ejection fraction</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Initiate only in stable, euvolemic patients. In hospitalized patients, volume status should be optimized and IV diuretics, IV vasodilators, and IV inotropic agents successfully discontinued prior to initiating therapy. Use caution when initiating in patients with New York Heart Association class IV symptoms or recent heart failure exacerbation (particularly if inotropes were required during hospital course) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Immediate release: Oral:</b> Initial: 3.125 mg twice daily; up-titrate gradually (eg, doubling the dose every ≥ 1 to 2 weeks) to the target dose while monitoring for signs and symptoms of heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499','lexi-content-ref-8614419','lexi-content-ref-11386263']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499','lexi-content-ref-8614419','lexi-content-ref-11386263'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Target dose:</p>
<p style="text-indent:-2em;margin-left:8em;">≤85 kg: 25 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;85 kg: 50 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extended release: Oral:</b> Initial: 10 mg once daily; up-titrate gradually (eg, doubling the dose every 1 to 2 weeks) to the target dose of 80 mg once daily while monitoring for signs and symptoms of heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Not recommended in the absence of specific comorbidities (eg, arrhythmia ischemic heart disease, heart failure with reduced ejection fraction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Immediate release: Oral:</b> Initial: 6.25 mg twice daily; titrate in ≥1-week intervals as needed based on patient response; usual dosage range: 6.25 to 25 mg twice daily; maximum dose: 50 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extended release: Oral:</b> Initial: 20 mg once daily; titrate in ≥1-week intervals as needed based on patient response; usual dosage range: 20 to 80 mg/day; maximum dose: 80 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="51b05bef-6600-468e-9957-c474e5eda739">Myocardial infarction, early treatment and secondary prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myocardial infarction, early treatment and secondary prevention (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> An <b>oral</b> beta-blocker is recommended within the first 24 hours for most patients. Patients who do not receive a beta-blocker within 24 hours of myocardial infarction due to contraindications should be reevaluated for secondary prevention at a later date (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23247304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23247304'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Immediate release: Oral:</b> Initial: 3.125 to 6.25 mg twice daily; titrate dose based on heart rate and blood pressure as tolerated up to 25 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11356434']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11356434'])">Ref</a></span>). The optimal duration of therapy is unknown; treat for a minimum of 3 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23247304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23247304'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c6cc9954-dac7-46ff-8fbb-4fd8de1d9ff9">Nonsustained ventricular tachycardia or ventricular premature beats, symptomatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nonsustained ventricular tachycardia or ventricular premature beats, symptomatic (off-label use)</b>
<b>: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Immediate release: Oral:</b> Initial: 3.125 mg twice daily; titrate as needed based on response and tolerability up to 25 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29097320']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29097320'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="510b7f04-3505-44ec-806a-308aae2e2c37">Variceal hemorrhage prophylaxis, primary</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Variceal hemorrhage prophylaxis, primary (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Immediate release: Oral:</b> Initial: 3.125 mg twice daily or 6.25 mg <b>once</b> daily; titrate according to resting heart rate (target 55 to 60 beats per minute) while maintaining blood pressure (eg, systolic blood pressure ≥90 mm Hg) to a maximum dose of 6.25 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27786365','lexi-content-ref-12447861','lexi-content-ref-27298379','lexi-content-ref-23250049','lexi-content-ref-Sanyal.2019','lexi-content-ref-19610055']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27786365','lexi-content-ref-12447861','lexi-content-ref-27298379','lexi-content-ref-23250049','lexi-content-ref-Sanyal.2019','lexi-content-ref-19610055'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Conversion from immediate release to extended release (Coreg CR):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Current dose IR tablets 3.125 mg twice daily: Convert to ER capsules 10 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Current dose IR tablets 6.25 mg twice daily: Convert to ER capsules 20 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Current dose IR tablets 12.5 mg twice daily: Convert to ER capsules 40 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Current dose IR tablets 25 mg twice daily: Convert to ER capsules 80 mg once daily.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990426"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Mild to severe impairment:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10424319','lexi-content-ref-1505616','lexi-content-ref-7681374']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10424319','lexi-content-ref-1505616','lexi-content-ref-7681374'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Poorly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1721982']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1721982'])">Ref</a></span>); no supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1378134','lexi-content-ref-1721982']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1378134','lexi-content-ref-1721982'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nemecek.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nemecek.1'])">Ref</a></span>); no dosage adjustment necessary (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987606"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: There are no dosage adjustments provided in the manufacturer's labeling; dose conservatively and interrupt therapy in the setting of hypotension (eg, mean arterial pressure [MAP] &lt;65 mm Hg), acute kidney injury, or hyponatremia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-27786365']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-27786365'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: Use is contraindicated per manufacturer; however, experts will use if indicated (eg, for variceal hemorrhage prophylaxis); dose conservatively and interrupt therapy in the setting of hypotension (eg, MAP &lt;65 mm Hg), acute kidney injury, or hyponatremia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-27786365']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-27786365'])">Ref</a></span>).</p></div>
<div class="block arsc drugH1Div" id="F56042802"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Bradyarrhythmias</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Beta-blockers may cause first-degree<b> atrioventricular </b>(AV) <b>block</b>, second-degree AV block, or<b> complete atrioventricular block</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15288162','lexi-content-ref-15234417']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15288162','lexi-content-ref-15234417'])">Ref</a></span>). At maintenance dosing, second- or third-degree AV block are less likely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2450898']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2450898'])">Ref</a></span>). Beta-blocking agents with intrinsic sympathomimetic activity (eg, pindolol) may cause fewer AV conduction abnormalities than those without intrinsic sympathomimetic activity (eg, carvedilol) due to their partial agonist effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2892986','lexi-content-ref-1977302','lexi-content-ref-2450898']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2892986','lexi-content-ref-1977302','lexi-content-ref-2450898'])">Ref</a></span>). In most cases (up to 72%), AV block associated with a beta-blocker will resolve upon discontinuation; however, there are reported cases of recurrent AV block and nearly 50% of patients with more severe AV block may require a permanent pacemaker (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22530749']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22530749'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; related to the pharmacologic action. Blockade of cardiac beta-1 adrenergic receptors results in slowed conduction and prolongation of the refractory period of the AV node. Slowing of AV conduction can lead to AV block (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15288162','lexi-content-ref-2450898']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15288162','lexi-content-ref-2450898'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; one study included patients who were on a beta-blocker for more than 1 month (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27899939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27899939'])">Ref</a></span>); however, other studies noted prolongation of the PR interval or AV nodal refractory period occurring anywhere from 1 dose to several days following treatment initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2897302','lexi-content-ref-2450898']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2897302','lexi-content-ref-2450898'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Impaired AV node conduction or sinus node function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15288162']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15288162'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other agents that impair AV nodal conduction (eg, nondihydropyridine calcium channel blockers, digoxin, ivabradine, select antiarrhythmic agents) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27899939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27899939'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27899939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27899939'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bronchospasm</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Nonselective beta-blockers (eg, carvedilol) have a higher risk of <b>bronchospasm</b> compared to cardioselective beta-blockers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27390282','lexi-content-ref-6344309']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27390282','lexi-content-ref-6344309'])">Ref</a></span>) and may lead to drug discontinuation in patients with chronic obstructive pulmonary diseases (COPD) or asthma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12490274','lexi-content-ref-6344309']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12490274','lexi-content-ref-6344309'])">Ref</a></span>). One study showed that patients with asthma and heart failure tolerated carvedilol poorly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12490274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12490274'])">Ref</a></span>). Concurrent use of inhaled bronchodilators and/or corticosteroids are protective against beta-blocker–induced bronchospasm in patients with COPD or asthma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12490274','lexi-content-ref-27390282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12490274','lexi-content-ref-27390282'])">Ref</a></span>). Bronchospasm is reversible upon discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2439802']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2439802'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; related to pharmacologic action. Beta-blocking agents can lead to airway smooth muscle constriction by antagonism of beta-2 receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15579370','lexi-content-ref-27390282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15579370','lexi-content-ref-27390282'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; changes in peak expiratory flow rates have occurred after 1 dose. Discontinuation due to carvedilol-induced bronchospasm varied from 5 days to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12490274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12490274'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Reactive airway disease (asthma) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12490274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12490274'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Beta-blockers may cause CNS effects such as <b>fatigue</b>, <b>sleep disorder</b>, <b>insomnia</b>, and vivid dreams (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969714','lexi-content-ref-12117400','lexi-content-ref-15288162','lexi-content-ref-1969642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969714','lexi-content-ref-12117400','lexi-content-ref-15288162','lexi-content-ref-1969642'])">Ref</a></span>). Memory impairment has been reported with carvedilol; however, newer data suggest it may be helpful for patients with Alzheimer disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17534003','lexi-content-ref-20579773']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17534003','lexi-content-ref-20579773'])">Ref</a></span>). Sexual disorders may occur; however, patients who require beta-blocker therapy have risk factors for erectile dysfunction (eg, coronary artery disease, heart failure) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Botros.1','lexi-content-ref-29746858','lexi-content-ref-11206674','lexi-content-ref-12117400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Botros.1','lexi-content-ref-29746858','lexi-content-ref-11206674','lexi-content-ref-12117400'])">Ref</a></span>). Lipophilic beta-blockers (such as carvedilol, which is highly lipophilic) penetrate the blood-brain barrier to a greater extent than hydrophilic beta-blockers, possibly leading to a greater incidence of CNS effects; however, other studies have refuted this theory (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969714','lexi-content-ref-1969642','lexi-content-ref-19724774','lexi-content-ref-2865153']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969714','lexi-content-ref-1969642','lexi-content-ref-19724774','lexi-content-ref-2865153'])">Ref</a></span>). CNS effects generally resolve with dose reduction or discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969714']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969714'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; exact mechanism is not fully understood. Proposed mechanisms include presence of beta receptors in the brain, affinity (and in some instances, inhibition) of beta-blocking agents towards serotonin (5-HT) receptors in the brain (affecting mood and sleep), and beta-blocker–induced decreases in central sympathetic output (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8956349','lexi-content-ref-2865151','lexi-content-ref-2878741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8956349','lexi-content-ref-2865151','lexi-content-ref-2878741'])">Ref</a></span>). Beta-1 blockade may also impact sleep by blocking sympathetic signaling to the pineal gland, resulting in suppression of nighttime levels of melatonin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23024438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23024438'])">Ref</a></span>). Beta-blockers may cause erectile dysfunction through decreased sympathetic nervous system output and subsequent decreases in luteinizing hormone secretion and testosterone stimulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24155101']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24155101'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Intermediate; CNS effects often occur within the first few weeks of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969714']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969714'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher starting doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969714']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969714'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969642'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Potentiation/masking of hypoglycemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beta-blockers may worsen, prolong, or cause <b>hypoglycemia </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2861072','lexi-content-ref-Vue.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2861072','lexi-content-ref-Vue.1'])">Ref</a></span>). Additionally, beta-blockers may mask symptoms of hypoglycemia (tremor, irritability, palpitations), making diaphoresis the only symptom unaffected by beta-blockers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vue.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vue.1'])">Ref</a></span>). It is unclear if nonselective or selective beta-blockers are more likely to cause hypoglycemia, as data are conflicting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15536109','lexi-content-ref-31775749','lexi-content-ref-20067434','lexi-content-ref-85053','lexi-content-ref-6376017','lexi-content-ref-Vue.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15536109','lexi-content-ref-31775749','lexi-content-ref-20067434','lexi-content-ref-85053','lexi-content-ref-6376017','lexi-content-ref-Vue.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; related to the pharmacologic action. Beta-blockers inhibit hepatic gluconeogenesis and glycogenolysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2861072','lexi-content-ref-Vue.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2861072','lexi-content-ref-Vue.1'])">Ref</a></span>). Beta-blockers also reduce activation of the sympathetic nervous system, therefore masking hypoglycemic symptoms that are catecholamine-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vue.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vue.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; hypoglycemia (&lt;70 mg/dL) was reported significantly more after 24 hours of carvedilol use compared to patients not on beta-blockers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31775749']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31775749'])">Ref</a></span>). In another study, episodes of severe hypoglycemia (&lt;50 mg/dL) were reported over the course of 4 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28559400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28559400'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Insulin-dependent diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2861072']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2861072'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Type 2 diabetes mellitus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28559400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28559400'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients who are hospitalized and not requiring basal insulin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31775749']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31775749'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Beta-blocker therapy should not be withdrawn abruptly but gradually tapered to avoid acute <b>tachycardia</b>, <b>hypertension</b>, and/or ischemia in patients with underlying cardiovascular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2897781','lexi-content-ref-2883874','lexi-content-ref-37093']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2897781','lexi-content-ref-2883874','lexi-content-ref-37093'])">Ref</a></span>). Some studies have found an increase in propensity-adjusted mortality and cardiovascular events; however, one study did not find changes in infarct size and left ventricular function when beta-blocker was abruptly withdrawn in patients with myocardial infarction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3009050','lexi-content-ref-18617067','lexi-content-ref-1968518']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3009050','lexi-content-ref-18617067','lexi-content-ref-1968518'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-dependent; related to the pharmacologic action. Beta blockade causes upregulation of beta receptors, enhanced receptor sensitivity, and decreased sympathetic nervous system response. Abrupt withdrawal leads to a transient sympathetic hyper-response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2883874','lexi-content-ref-37093','lexi-content-ref-6125186','lexi-content-ref-6125187']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2883874','lexi-content-ref-37093','lexi-content-ref-6125186','lexi-content-ref-6125187'])">Ref</a></span>). Another proposed mechanism involves increased platelet aggregability to epinephrine and thrombin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2883874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2883874'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid/varied and transient; increases in heart rate and blood pressure appear 24 hours after abrupt withdrawal, peak after 48 hours, and subside after 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37093']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37093'])">Ref</a></span>). In other nonselective beta-blockers (propranolol), anginal symptoms are reported to begin 12 to 24 hours after discontinuation. Development of adverse reactions is also reported to occur 1 to 21 days after withdrawal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2897781','lexi-content-ref-1244260','lexi-content-ref-668066']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2897781','lexi-content-ref-1244260','lexi-content-ref-668066'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Abrupt withdrawal in chronic users (Lederballe Pederson 1979)</p>
<p style="text-indent:-2em;margin-left:6em;">• Past medical history of coronary artery disease (including chronic stable angina) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2897781','lexi-content-ref-2883874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2897781','lexi-content-ref-2883874'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Past medical history of hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37093','lexi-content-ref-1968518']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37093','lexi-content-ref-1968518'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F146660"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults administered immediate release (IR), unless otherwise noted as extended release (ER).</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (≤20%), orthostatic hypotension (≤20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia (5% to 12%), weight gain (10% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (IR: 2% to 12%; ER: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (11%), dizziness (IR: 6% to 32%; ER: 2%), fatigue (24%)<span class="lexi-table-link-container"> (<a aria-label="Fatigue table link" class="lexi-table-link" data-table-id="lexi-content-fatigue" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-fatigue')">table 1</a>)</span><span class="table-link" style="display:none;">Fatigue</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Fatigue" frame="border" id="lexi-content-fatigue" rules="all">
<caption style="text-align:center;">
<b>Carvedilol: Adverse Reaction: Fatigue</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Carvedilol)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Carvedilol)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">24%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Mild to moderate heart failure</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">765</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">437</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris (6%), atrioventricular block (1% to 3%; complete atrioventricular block [&lt;1%]), bradycardia (IR: 2% to 10%; ER: &lt;1%)<span class="lexi-table-link-container"> (<a aria-label="Bradycardia table link" class="lexi-table-link" data-table-id="lexi-content-bradycardia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-bradycardia')">table 2</a>)</span><span class="table-link" style="display:none;">Bradycardia</span>, dependent edema (4%), edema (5% to 6%), exacerbation of angina pectoris (1% to 3%), hypertension (1% to 3%), lower extremity edema (1% to 3%), palpitations (1% to 3%), peripheral edema (IR: 1% to 7%; ER: 2%), peripheral ischemia (≤1%), peripheral vascular disease (1% to 3%), syncope (IR: ≤8%; ER: &lt;1%), tachycardia (≤1%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Bradycardia" frame="border" id="lexi-content-bradycardia" rules="all">
<caption style="text-align:center;">
<b>Carvedilol: Adverse Reaction: Bradycardia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Carvedilol)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Carvedilol)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Heart failure or myocardial infarction/left ventricular dysfunction</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hypertension</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,142</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">462</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Mild to moderate heart failure</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">765</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">437</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Myocardial infarction and left ventricular dysfunction</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Severe heart failure</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,156</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,133</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (≤1%), erythematous rash (≤1%), maculopapular rash (≤1%), pruritus (≤1%), psoriasiform eruption (≤1%), skin photosensitivity (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Albuminuria (1% to 3%), decreased libido (≤1%), diabetes mellitus (1% to 3%), hypercholesterolemia (4%), hyperkalemia (1% to 3%), hypertriglyceridemia (≤1%), hyperuricemia (1% to 3%), hypervolemia (1% to 3%), hypoglycemia (1% to 3%), hypokalemia (≤1%), hyponatremia (1% to 3%), hypovolemia (1% to 3%), increased nonprotein nitrogen (6%), weight loss (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal pain (1% to 3%), melena (1% to 3%), nausea (IR: 4% to 9%; ER: 2%), periodontitis (1% to 3%), vomiting (6%), xerostomia (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Erectile dysfunction (1% to 3%), glycosuria (1% to 3%), hematuria (1% to 3%), urinary frequency (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hypoprothrombinemia (1% to 3%), leukopenia (≤1%), purpuric disease (1% to 3%), thrombocytopenia (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased gamma-glutamyl transferase (1% to 3%), increased serum alanine aminotransferase (1% to 3%), increased serum alkaline phosphatase (1% to 3%), increased serum aspartate aminotransferase (1% to 3%), increased serum bilirubin (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebrovascular accident (1% to 3%), changes in thinking (≤1%), depression (1% to 3%), drowsiness (1% to 3%), emotional lability (≤1%), exacerbation of depression (≤1%), headache (5% to 8%), hypoesthesia (1% to 3%), hypotonia (1% to 3%), insomnia (IR: 2%; ER: 1%)<span class="lexi-table-link-container"> (<a aria-label="Insomnia table link" class="lexi-table-link" data-table-id="lexi-content-insomnia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-insomnia')">table 3</a>)</span><span class="table-link" style="display:none;">Insomnia</span>, lack of concentration (≤1%), malaise (1% to 3%), nervousness (≤1%), nightmares (≤1%), paranoid ideation (≤1%), paresthesia (IR: 1% to 3%; ER: 1%), sleep disturbance (≤1%), vertigo (1% to 3%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Insomnia" frame="border" id="lexi-content-insomnia" rules="all">
<caption style="text-align:center;">
<b>Carvedilol: Adverse Reaction: Insomnia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Carvedilol)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Carvedilol)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hypertension</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,142</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">462</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hypertension</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">253</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">84</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (6%), arthritis (1% to 3%), gout (1% to 3%), hypokinesia (≤1%), muscle cramps (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (1% to 3%), visual disturbance (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen (≤6%), increased serum creatinine (1% to 3%), kidney impairment (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma (≤1%), dyspnea (&gt;3%), flu-like symptoms (1% to 3%), increased cough (5%), nasal congestion (ER: 1%), nasopharyngitis (ER: 4%), paranasal sinus congestion (ER: 1%), rales (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bundle branch block, ischemic heart disease</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, exfoliative dermatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased HDL cholesterol, respiratory alkalosis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Abnormal lymphocytes, pancytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Amnesia, cerebrovascular disease, migraine, neuralgia, paresis, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Auditory impairment</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined (any formulation):</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pulmonary edema</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any formulation):</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme, Stevens-Johnson syndrome (Kowalski 1997), toxic epidermal necrolysis (Vlahovic-Palcevski 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary incontinence</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Aplastic anemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity (including toxic hepatitis) (Hagmeyer 2001; Rua 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial pneumonitis</p></div>
<div class="block coi drugH1Div" id="F146676"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Serious hypersensitivity to carvedilol or any component of the formulation; decompensated cardiac failure requiring intravenous inotropic therapy; bronchial asthma or related bronchospastic conditions; second- or third-degree AV block, sick sinus syndrome, or severe bradycardia (except in patients with a functioning artificial pacemaker); cardiogenic shock; severe hepatic impairment</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Severe hypotension; primary obstructive valvular heart disease; mental incapacity (eg, severe Alzheimer disease, alcoholism, drug abuse), unless closely supervised by an appropriate caregiver.</p></div>
<div class="block war drugH1Div" id="F146657"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bradycardia: May occur; reduce dosage if heart rate drops to &lt;55 beats/minute.</p>
<p style="text-indent:-2em;margin-left:4em;">• Floppy iris syndrome: Intraoperative floppy iris syndrome has been observed in cataract surgery patients who were on or were previously treated with alpha<sub>1</sub>-blockers; there appears to be no benefit in discontinuing alpha-blocker therapy prior to surgery. Instruct patients to inform ophthalmologist of carvedilol use when considering eye surgery.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension/syncope: Symptomatic hypotension with or without syncope may occur with carvedilol (usually within the first 30 days of therapy); close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Initiation with a low dose, gradual up-titration, and administration with food may help to decrease the occurrence of hypotension or syncope. Advise patients to avoid driving or other hazardous tasks during initiation of therapy due to the risk of syncope.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Angina: Use with caution in patients suspected of having vasospastic angina.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; if used at all, should be used cautiously with close monitoring.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms (eg, sweating, anxiety, tachycardia). In patients with heart failure and diabetes, use of carvedilol may worsen hyperglycemia; may require adjustment of antidiabetic agents.</p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure with reduced ejection fraction: Stabilize patients on heart failure regimen prior to initiation or titration of beta-blocker. Beta-blocker therapy should be initiated at very low doses with gradual and careful titration. Worsening heart failure or fluid retention may occur during upward titration; dose reduction and/or slower titration may be necessary. Adjustment of other medications (ACE inhibitors and/or diuretics) may also be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use with caution in patients with myasthenia gravis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Peripheral vascular disease (PVD): May precipitate or aggravate symptoms of arterial insufficiency in patients with PVD; use with caution and monitor for progression of arterial obstruction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pheochromocytoma (untreated): Use with caution; adequate alpha-blockade should be initiated prior to use of any beta-blocker.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psoriasis: Beta-blocker use has been associated with induction or exacerbation of psoriasis, but cause and effect have not been firmly established.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If hyperthyroidism is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Bradycardia may be observed more frequently in elderly patients (&gt;65 years of age); dosage reductions may be necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and kidney and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abrupt withdrawal: Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered to avoid acute tachycardia, hypertension, and/or ischemia. Severe exacerbation of angina, ventricular arrhythmias, and myocardial infarction (MI) have been reported following abrupt withdrawal of beta-blocker therapy. Temporary and prompt resumption of beta-blocker therapy may be indicated with worsening of angina or acute coronary insufficiency.</p>
<p style="text-indent:-2em;margin-left:4em;">• Major surgery: Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.</p></div>
<div class="block foc drugH1Div" id="F146669"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release 24 Hour, Oral, as phosphate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Coreg CR: 10 mg, 20 mg, 40 mg, 80 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 20 mg, 40 mg, 80 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Coreg: 3.125 mg, 6.25 mg, 12.5 mg, 25 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 3.125 mg, 6.25 mg, 12.5 mg, 25 mg</p></div>
<div class="block geq drugH1Div" id="F146653"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F146679"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Carvedilol Phosphate ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $9.91 - $20.44</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $9.91 - $20.44</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $9.91 - $20.44</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $9.91 - $20.44</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Coreg CR Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $37.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $37.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $37.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $37.14</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Carvedilol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3.125 mg (per each): $0.21 - $2.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6.25 mg (per each): $0.06 - $2.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg (per each): $0.07 - $2.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.09 - $2.14</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Coreg Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3.125 mg (per each): $11.81</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6.25 mg (per each): $11.81</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg (per each): $11.81</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $11.81</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866211"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 3.125 mg, 6.25 mg, 12.5 mg, 25 mg</p></div>
<div class="block exp drugH1Div" id="F11339554"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Multiple recipes for extemporaneously prepared suspensions exist; American Society of Health-System Pharmacists (ASHP) does not have a recommendation for a standard concentration; use caution and consult institutional protocols:</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>1.25 mg/mL oral suspension</b></p>
<p style="text-indent:-2em;margin-left:4em;">A 1.25 mg/mL carvedilol oral suspension may be made with tablets and one of two different vehicles (Ora-Blend or 1:1 mixture of Ora-Sweet and Ora-Plus). Crush five 25 mg tablets in a mortar and reduce to a fine powder; add 15 mL of purified water and mix to a uniform paste. Mix while adding chosen vehicle in incremental proportions to almost 100 mL; transfer to a calibrated amber bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 100 mL. Label “shake well.” Stable for 84 days when stored in amber prescription bottles at room temperature (Loyd 2006).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>0.1 and 1.67 mg/mL oral suspensions</b></p>
<p style="text-indent:-2em;margin-left:4em;">Carvedilol oral liquid suspensions (0.1 mg/mL and 1.67 mg/mL) made from tablets, water, Ora-Plus, and Ora-Sweet were stable for 12 weeks when stored in glass amber bottles at room temperature (25°C). Use one 3.125 mg tablet for the 0.1 mg/mL suspension or two 25 mg tablets for the 1.67 mg/mL suspension; grind the tablet(s) and compound a mixture with 5 mL of water, 15 mL Ora-Plus, and 10 mL Ora-Sweet. Final volume of each suspension: 30 mL; label “shake well” (data on file, GlaxoSmithKline, Philadelphia, PA: DOF #132 [<b>Note:</b> Manufacturer no longer disseminates this document]).</p>
<div class="reference">Loyd A Jr, “Carvedilol 1.25 mg/mL Oral Suspension,” <i>Int J Pharm Compounding</i>, 2006, 10(3):220.</div>
</div>
<div class="block admp drugH1Div" id="F52612371"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Immediate-release tablets: Administer with food.</p></div>
<div class="block adm drugH1Div" id="F146673"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer with food to minimize the risk of orthostatic hypotension. Extended-release capsules and its contents should not be crushed, chewed, or divided. Capsules may be opened and its contents sprinkled on applesauce for immediate use.</p></div>
<div class="block sts drugH1Div" id="F146691"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Coreg: Store at &lt;30°C (&lt;86°F). Protect from moisture.</p>
<p style="text-indent:-2em;margin-left:2em;">Coreg CR: Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light.</p></div>
<div class="block usep drugH1Div" id="F53565876"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of mild to severe chronic heart failure of cardiomyopathic or ischemic origin (usually in addition to standard therapy) (FDA approved in ages ≥18 years and adults); management of essential hypertension, alone or in combination with other agents (FDA approved in ages ≥18 years and adults); reduction of cardiovascular mortality in patients with left ventricular dysfunction (ejection fraction ≤40%) following myocardial infarction (FDA approved in ages ≥18 years and adults).</p></div>
<div class="block mst drugH1Div" id="F146750"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Carvedilol may be confused with atenolol, captopril, carbidopa, carteolol</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Coreg may be confused with Corgard, Cortef, Cozaar</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F146735"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2C9 (major), CYP2D6 (major), CYP2E1 (minor), CYP3A4 (minor), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> P-glycoprotein/ABCB1</p></div>
<div class="block dri drugH1Div" id="F146662"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Afatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.  Management: If combined, administer the P-gp inhibitor simultaneously with, or after, the dose of afatinib. Monitor closely for signs and symptoms of afatinib toxicity and if the combination is not tolerated, reduce the afatinib dose by 10 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Beta-Blockers (Nonselective) may enhance the hypoglycemic effect of Antidiabetic Agents. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Berotralstat: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Berotralstat.  Management: Decrease the berotralstat dose to 110 mg daily when combined with P-glycoprotein (P-gp) inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bilastine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bilastine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: Beta-Blockers may enhance the adverse/toxic effect of Cannabis. Specifically, the risk of hypoglycemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Celiprolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Celiprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: This combination is often contraindicated, but combined use may be permitted with dose adjustment and monitoring. Recommendations vary based on brand, indication, use of CYP3A4 inhibitors, and hepatic/renal function. See interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C9 Inhibitors (Moderate): May increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Moderate): May increase the serum concentration of Carvedilol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Strong): May increase the serum concentration of Carvedilol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: May enhance the bradycardic effect of Carvedilol. Carvedilol may increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disopyramide: May enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may enhance the negative inotropic effect of Disopyramide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOBUTamine: Beta-Blockers may diminish the therapeutic effect of DOBUTamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Liposomal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose. Increase monitoring for clinical response and adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Edoxaban. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPHEDrine (Systemic): Beta-Blockers may diminish the therapeutic effect of EPHEDrine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Nasal): Beta-Blockers (with Alpha-Blocking Properties) may diminish the therapeutic effect of EPINEPHrine (Nasal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Oral Inhalation): Beta-Blockers (with Alpha-Blocking Properties) may diminish the therapeutic effect of EPINEPHrine (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Epinephrine (Racemic): Beta-Blockers (with Alpha-Blocking Properties) may diminish the therapeutic effect of Epinephrine (Racemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Systemic): Beta-Blockers (with Alpha-Blocking Properties) may diminish the therapeutic effect of EPINEPHrine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etilefrine: May enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may diminish the therapeutic effect of Etilefrine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etofylline: Beta-Blockers may diminish the therapeutic effect of Etofylline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Etoposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide Phosphate: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Etoposide Phosphate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grass Pollen Allergen Extract (5 Grass Extract): Beta-Blockers may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). More specifically, Beta-Blockers may inhibit the ability to effectively treat severe allergic reactions to Grass Pollen Allergen Extract (5 Grass Extract) with epinephrine.  Some other effects of epinephrine may be unaffected or even enhanced (e.g., vasoconstriction) during treatment with Beta-Blockers.  Management: Consider alternatives to either grass pollen allergen extract (5 grass extract) or beta-blockers in patients with indications for both agents.  Canadian product labeling specifically lists this combination as contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Insulins: Beta-Blockers (Nonselective) may enhance the hypoglycemic effect of Insulins. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Insulins. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoproterenol: Beta-Blockers may diminish the therapeutic effect of Isoproterenol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Lapatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Larotrectinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Larotrectinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Lefamulin.  Management: Avoid concomitant use of lefamulin tablets with P-glycoprotein/ABCB1 inhibitors. If concomitant use is required, monitor for lefamulin adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may increase the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: Beta-Blockers may enhance the adverse/toxic effect of Mavacamten. Specifically, negative inotropic effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxyflurane: May enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: Beta-Blockers may enhance the therapeutic effect of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Morphine (Systemic): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Morphine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Nadolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naloxegol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: May enhance the hypotensive effect of Beta-Blockers. NIFEdipine may enhance the negative inotropic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrendipine: May enhance the therapeutic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May diminish the therapeutic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Patiromer: May decrease the serum concentration of Carvedilol. Management: Administer carvedilol at least 3 hours before or 3 hours after patiromer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pralsetinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pralsetinib.  Management: If this combo cannot be avoided, decrease pralsetinib dose from 400 mg daily to 300 mg daily; from 300 mg daily to 200 mg daily; and from 200 mg daily to 100 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ranolazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Relugolix.  Management: Avoid coadministration of relugolix with oral P-gp inhibitors whenever possible. If combined, take relugolix at least 6 hours prior to the P-gp inhibitor and monitor patients more frequently for adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix, Estradiol, and Norethindrone: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Relugolix, Estradiol, and Norethindrone.  Management: Avoid use of relugolix/estradiol/norethindrone with P-glycoprotein (P-gp) inhibitors. If concomitant use is unavoidable, relugolix/estradiol/norethindrone should be administered at least 6 hours before the P-gp inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Repotrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reserpine: May enhance the bradycardic effect of Beta-Blockers. Reserpine may enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Carvedilol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAXIMin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RifAXIMin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rimegepant.  Management: Avoid administration of another dose of rimegepant within 48 hours if given concomitantly with a P-glycoprotein (P-gp) inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RisperiDONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: May enhance the bradycardic effect of Beta-Blockers.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RomiDEPsin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RomiDEPsin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Saquinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Sirolimus (Conventional).  Management: Avoid concurrent use of sirolimus with P-glycoprotein (P-gp) inhibitors when possible and alternative agents with lesser interaction potential with sirolimus should be considered. Monitor for increased sirolimus concentrations/toxicity if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Sirolimus (Protein Bound). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Beta-Blockers may enhance the neuromuscular-blocking effect of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Beta-Blockers (Nonselective) may enhance the hypoglycemic effect of Sulfonylureas. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talazoparib: Carvedilol may increase the serum concentration of Talazoparib.  Management: In breast cancer, if concurrent use cannot be avoided, reduce talazoparib dose to 0.75 mg once daily. In prostate cancer, monitor patients for increased adverse events.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tasimelteon: Beta-Blockers may diminish the therapeutic effect of Tasimelteon.  Management: Consider avoiding nighttime administration of beta-blockers during tasimelteon therapy due to the potential for reduced tasimelteon efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tegaserod (Withdrawn from US Market): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tegaserod (Withdrawn from US Market). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teniposide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Teniposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Disoproxil Fumarate: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tenofovir Disoproxil Fumarate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 50 mg and second dose (at least 2 hours later if needed) of 50 mg when used with a P-gp inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venetoclax: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Venetoclax.  Management: Reduce the venetoclax dose by at least 50% in patients requiring concomitant treatment with P-glycoprotein (P-gp) inhibitors. Resume the previous venetoclax dose 2 to 3 days after discontinuation of a P-gp inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">White Birch Allergen Extract: Beta-Blockers may enhance the adverse/toxic effect of White Birch Allergen Extract. Specifically, beta-blockers may reduce the effectiveness of beta-agonists that may be required to treat systemic reactions to white birch allergen extract. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F146692"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food decreases rate but not extent of absorption. Management: Administration with food minimizes risks of orthostatic hypotension.</p></div>
<div class="block dic drugH1Div" id="F146681"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Should be taken with food to minimize the risk of orthostatic hypotension.</p></div>
<div class="block rep_considerations drugH1Div" id="F58703601"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be used in patients trying to conceive. Carvedilol is not considered a preferred agent for use in pregnant patients; consider transitioning to a preferred agent in patients planning to become pregnant (ACC/AHA [Whelton 2018]; ACOG 2019; NICE 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Impotence is noted in product labeling following use of carvedilol. As a class, outcomes from available studies evaluating beta-blockers and sexual dysfunction are inconsistent, and the negative effects on erectile function are considered controversial. A clear relationship between use of beta-blockers and erectile dysfunction has not been established. Hypertension itself is associated with erectile dysfunction. Patients on a beta-blocker presenting with sexual dysfunction should be evaluated for underlying disease (Farmakis 2022; Levine 2012; Semet 2017; Terentes-Printzios 2022; Viigimaa 2020).</p></div>
<div class="block pri drugH1Div" id="F146680"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Exposure to beta-blockers during pregnancy may increase the risk for adverse events in the neonate. If maternal use of a beta-blocker is needed, monitor fetal growth during pregnancy; monitor the newborn for 48 hours after delivery for bradycardia, hypoglycemia, and respiratory depression (ESC [Regitz-Zagrosek 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">Chronic maternal hypertension is also associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Patients with preexisting hypertension may continue their medication during pregnancy unless contraindications exist (ESC [Regitz-Zagrosek 2018]). When treatment of hypertension is initiated during pregnancy, agents other than carvedilol may be preferred (ACOG 2019; ESC [Cífková 2020]; ESC [Regitz-Zagrosek 2018]; SOGC [Magee 2022]). Carvedilol may be considered for use in pregnant patients with heart failure (ESC [Regitz-Zagrosek 2018]).</p></div>
<div class="block mopp drugH1Div" id="F53565877"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Heart rate, blood pressure, weight, SCr, BUN, liver function; in patient with increased risk for developing renal dysfunction, monitor renal function during dosage titration.</p></div>
<div class="block pha drugH1Div" id="F146656"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">As a racemic mixture, carvedilol has nonselective beta-adrenoreceptor and alpha-adrenergic blocking activity. No intrinsic sympathomimetic activity has been documented. Associated effects in hypertensive patients include reduction of cardiac output, exercise- or beta-agonist-induced tachycardia, reduction of reflex orthostatic tachycardia, vasodilation, decreased peripheral vascular resistance (especially in standing position), decreased renal vascular resistance, reduced plasma renin activity, and increased levels of atrial natriuretic peptide. In CHF, associated effects include decreased pulmonary capillary wedge pressure, decreased pulmonary artery pressure, decreased heart rate, decreased systemic vascular resistance, increased stroke volume index, and decreased right atrial pressure (RAP).</p></div>
<div class="block phk drugH1Div" id="F146675"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Antihypertensive effect: Alpha-blockade: Within 30 minutes; Beta-blockade: Within 1 hour</p>
<p style="text-indent:-2em;margin-left:4em;">Peak antihypertensive effect: ~1 to 2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Rapid and extensive, but with large first pass effect; first pass effect is stereoselective with R(+) enantiomer achieving plasma concentrations 2 to 3 times higher than S(-) enantiomer; delayed with food</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 115 L; distributes into extravascular tissues</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;98%, primarily to albumin</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively (98%) hepatic, via CYP2C9, 2D6, 3A4, 2C19, 1A2, and 2E1 (2% excreted unchanged); metabolized predominantly by aromatic ring oxidation and glucuronidation; oxidative metabolites undergo conjugation via glucuronidation and sulfation; three active metabolites (4-hydroxyphenyl metabolite is 13 times more potent than parent drug for beta-blockade, however, active metabolites achieve plasma concentrations of only 1/10 of those for carvedilol); first-pass effect; plasma concentrations in the elderly and those with cirrhotic liver disease are 50% and 4 to 7 times higher, respectively. Metabolism is subject to genetic polymorphism; CYP2D6 poor metabolizers have a 2- to 3-fold higher plasma concentration of the R(+) enantiomer and a 20% to 25% increase in the S(-) enantiomer compared to extensive metabolizers.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Immediate release: ~25% to 35% (due to significant first-pass metabolism); Extended release: ~85% of immediate release; high-fat meal increases AUC and C<sub>max</sub> ~20%; bioavailability is increased in patients with CHF</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children 6 weeks to 3.5 years (n=8): 2.2 hours (Läer 2002)</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents 5.5 to 19 years (n=7): 3.6 hours (Läer 2002)</p>
<p style="text-indent:-2em;margin-left:4em;">Adults 7 to 10 hours; some have reported lower values: Adults 24 to 37 years (n=9): 5.2 hours (Läer 2002)</p>
<p style="text-indent:-2em;margin-left:4em;">R(+)-carvedilol: 5 to 9 hours</p>
<p style="text-indent:-2em;margin-left:4em;">S(-)-carvedilol: 7 to 11 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Extended release: ~5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily feces; urine (&lt;2%, unchanged)</p></div>
<div class="block phksp drugH1Div" id="F51192705"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Plasma concentrations may be higher (40% to 50% in moderate to severe kidney impairment).</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Severe hepatic impairment (cirrhosis) patients have a 4- to 7-fold increase in concentrations.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Plasma levels are about 50% higher.</p>
<p style="text-indent:-2em;margin-left:2em;">Heart failure: AUC and C<sub>max</sub> increased up to 100%.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F146682"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apo carvedilol | Carvidol | Coronis | Dilatrend</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Antibloc | Apo carvedilol | Bidecar | Bidecar cr | Cardionorm | Cartiato | Carvedil | Carvedilol biotenk | Carvedilol Hlb | Carvedilol northia | Carvedilol Richet | Carvicord | Carvipaw | Cloraten | Conalend | Corafen | Coritensil | Corubin | Dilatrend | Dilatrend AP | Duobloc | Entarsol | Filten | Filten lp | Hipoten | Isobloc | Isobloc cr | Kollosteril | Nexocardil | Pluscor | Rudoxil CR | Vedilep | Veraten | Veraten UD | Vicardol</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Carvedilol +pharma | Carvedilol 1a | Carvedilol genericon | Carvedilol hexal | Carvedilol Pfizer | Carvedilol ratiopharm | Carvedilol sandoz | Carvedilol stada arzneimittel gmbh | Dilatrend</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo carvedilol | Carvedilol an | Carvedilol generichealth | Carvedilol sandoz | Carvidol | Dicarz | Dilasig | Dilatrend | Genrx Carvedilol | GN-Carvedilol | Kredex | Vedilol | Volirop</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Avidol | Cardivas | Carved | Carvida | Carviloc | Carvista | Cavelon | Dilapress | Dilatrend | Dilgard | Dilocard | Dilol | Diola | Durol | Karvedil | Koreg | Revodil | Ucardol | Vedilol | Vesodil</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Carvedilol Apotex | Carvedilol bexal | Carvedilol Eurogenerics | Carvedilol merck-generics | Carvedilol ratiopharm | Carvedilol sandoz | Carvedilol teva | Dimitone | Doccarvedilol | Kredex</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Carvedi denk</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Carvedigamma | Carvedil | Carvedilol ratiopharm | Carvilex | Coryol | Dilatrend | Talliton</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Becarve | Cardbet | Cardilol | Carvedilat | Carvegran | Corediol | Coreg | Cronocor | Dilatrend | Divelol | Ictus | Karvil | Nienza</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Carvedilol Adico | Carvedilol Helvepharm | Carvedilol mepha | Carvedilol sandoz | Carvedilol spirig hc | Carvedilol teva | Carvedilol zentiva | Dilatrend</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Carvedi denk | Carvepro | Cavdiol</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Betaplex | Blocar | Dicartel | Dilatrend | Dualten | Lodipres | Novocar | Off-Ten</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Dilatrend | Jin luo | Kai luo | Kang da xin | Ke wei de | Lao de | Rui xin le | Shu heng | Tuo er | Zhuo yi</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Betaplex | Cardancor | Cardoz | Carvedil | Coryol | Dilatrend | Expodilol | Tenvedil | Vasodyl</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo carve | Atram | Carvedigamma | Carvedilol orion | Carvedilol ratiopharm | Carvedilol teva | Carvesan | Carvetrend | Coryol | Dilatrend | Kredex | Ocarox | Talliton</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Carlich | Carve tad | Carve-Q | Carvecard | Carvedi denk | Carvedigamma | Carvedilol 1a pharma | Carvedilol AbZ | Carvedilol Acis | Carvedilol Actavis | Carvedilol al | Carvedilol Atid | Carvedilol aurobindo | Carvedilol Aurus | Carvedilol Axcount | Carvedilol beta | Carvedilol Corax | Carvedilol CT | Carvedilol dura | Carvedilol Heumann | Carvedilol hexal | Carvedilol Isis | Carvedilol Kwizda | Carvedilol ratiopharm | Carvedilol sandoz | Carvedilol stada | Carvedilol teva | Carvedilol wolff | Dilatrend | Dimetil | Querto | Sigadilol</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Carvedilol gea | Carvedilol ratiopharm</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Adacor | Bloquedil | Bloquiber | Britavilol | Cadalol | Car | Carbaline | Cardiofel | Cardiosil | Cardivas | Carvechem | Carved | Carvedi-Pres | Carveten | Carvilar | Carvrem | Coreg | Corselet | Curpinol | Dilox | Eucor | Fibrilan | Filten | Fravedilol | Nicorax | Oroflam</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Betaplex | Carvedichem | Carvedil | Carvedilol nifa | Carvegran | Carvess | Cepiron | Cliarvas | Corubin | Coryol | Dilatrend | Ecopress | Ecopress carvedilol | Isobloc</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Atram | Avedol | Carvedilol genericon | Carvedilolhexal | Carvetrend | Coryol | Dilatrend | Kredex</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cardilol | Carlol v | Carvena | Carvid | Carviloc | Carvipress | Dilatrend | Dilatrol | Karvex | Vedocard</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Carvedilol acost | Carvedilol Almus | Carvedilol alter | Carvedilol amneal | Carvedilol Arafarma | Carvedilol aurobindo | Carvedilol aurovitas | Carvedilol bexal | Carvedilol Bexalabs | Carvedilol Cinfa | Carvedilol combix | Carvedilol edigen | Carvedilol Kern Pharma | Carvedilol Korhispana | Carvedilol krka | Carvedilol Normon | Carvedilol pharmacia | Carvedilol Pharmagenus | Carvedilol sandoz | Carvedilol ur | Carvedilol Winthrop | Coropres | Kredex | Palacimol</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Carca | Carvedi denk | Gladycor</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cardiol | Carvedilol Actavis | Carvedilol alpharm | Carvedilol Alpharma | Carvedilol alternova | Carvedilol generic | Carvedilol hexal | Carvedilol orion | Carvedilol Pfizer | Carvedilol ratiopharm | Carvedilol sandoz | Carvedilol stada | Carveratio | Carvetone | Karvedilol ivax</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Carvedilol arrow | Carvedilol biogaran | Carvedilol Dci | Carvedilol eg | Carvedilol Pfizer | Kredex</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Carvedilol Almus | Carvedilol arrow | Carvedilol cox | Carvedilol kent | Carvedilol sandoz | Eucardic</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Carvedilen | Carvedilol Generix | Carvedilol/mylan | Carvepen | Dilatrend | Ervidol</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo carvedilol | Dilatrend</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Cadil | Carvelol | Carvetrend | Coryol</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Carvedilol hexal | Carvedilol Pfizer | Carvedilol ratiopharm | Carvedilol zentiva | Carvetrend | Carvol | Dilatrend | Talliton</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Blorec | Dilbloc | V-Bloc</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Biocard | Eucardic | Kredex</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Carvedexxon | Carvedilol teva | Dimitone</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Caditone | Carca | Cardilox | Cardinorm | Cardipure | Cardivas | Cardivas cr | Carelol | Carloc | Cartab | Carvalol | Carvas | Carvedil | Carvefine | Carvenol | Carvetrend | Carvidex | Carviflo | Carvil | Carvimed | Carvipress | Carvistar | Carvizest | Carzec | Caslot | Cevas | Conpres | Cvl | Kar b | Oricar | Sazocard | Ved</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Awacarvedol | Karvedol</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Acarden | Caravel | Carvedilolo | Carvedilolo Actavis | Carvedilolo age | Carvedilolo almus | Carvedilolo aurobindo | Carvedilolo Awp | Carvedilolo doc | Carvedilolo eg | Carvedilolo Fg | Carvedilolo Pfizer | Carvedilolo Ranbaxy | Carvedilolo sigma tau | Carvedilolo Winthrop | Carvipress | Colver | Curcix | Dilatrend | Omeria | Trakor</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Cardilol | Carvidol | Dilatrend | Unidil</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Anisto | Artione | Artist | Atenote | Carvedilol dsep | Carvedilol hexal | Carvedilol jdolph | Carvedilol me | Carvedilol Nipro Pharma | Carvedilol Pfizer | Carvedilol sawai | Carvedilol Tatumi</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Arveda | Cadalol | Caravel | Carca | Cardivas | Cardivel | Cardoz | Carvas | Carvedi denk | Carvedilol sandoz | Carvil | Dilatrend | Karvil | Unidil | Vacodil | Vidol | Xicard</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ahngook carvedilol | Alpadilol | Alphadilol | Alveca | Alverol | Alvogen carvedilol | Binex carbedilol | Boryung carvedilol | Cabetren | Cadilan | Cadilen | Cadilol | Cadiron | Carave | Cardinal | Cardiren | Cardirone | Cardlol | Carp | Carve | Carvedi | Carvedia | Carvedian | Carvedil | Carvedilol kn | Carvee | Carvel | Carvelix | Carvella | Carvelol | Carvenal | Carvenil | Carveol | Carverol | Carveron | Carveta | Carvewin | Carvilol | Cavadil | Cave ct | Cavedil | Cavedin | Cavedol | Cavelil | Cavereu | Caverol | Caveron | Coverdilol | Dalat | Dicarvem | Diladol | Dilatrend | Dilatrend sr | Dilatrol | Dilavedil | Dilaverol | Dirant | Duvelol | Glodiol | I carvedil | Intrack | Karter | Kyongbo carvedilol | Newcarvelo | Newdilren | Oneverol | Pavedil | Sandoz carvedilol | Seoul carvedilol | Vasodilren | Vasotrol | Vedilol | Wonvelol</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Carvedilol hexal | Dilatrend | Unidil</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Cardilol | Carvedilol arrow | Dilatrend</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Atram | Cardiostad | Carvedilol teva | Carvedilolhexal | Carvetrend | Coryol | Cvdol | Dilatrend | Karvidil | Kredex | Talliton</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Carvedilol eg | Carvedilol Eurogenerics | Carvedilol ratiopharm | Dimitone | Doccarvedilol | Kredex</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Avedol | Cardiostad | Carvedilol genericon | Carvedilol hexal | Coryol | Dilatrend | Karvidil | Kredex</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Cardinor | Cardix | Carvedilol Gt | Celeno | Coronat | Dicarvel | Dilatrend | Dilovac | Xedilol</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Bloqadre | Cavarmis | Crabudol | Dilatrend | Torvedol</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo carvedilol | Cardiol | Carvedilol hexal | Carvepen | Caslot | Cavel | Dilatrend | Ditran | Vacodil</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Kuka carvedilol | Viedilol</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Carvedilol Merck | Carvedilol PCH | Carvedilol ratiopharm | Carvedilol teva | Eucardic</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Carvedilol aristo | Carvedilol aurobindo | Carvedilol hexal | Carvedilol Pfizer | Dilatrend | Kredex</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Carvedilol sandoz | Dicarz | Dilatrend</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Betacar | Cardiodil | Cardivas | Carvedil | Carveditas | Carvidex | Cepiron | Dilatrend | Favidiol</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Betacard | Betadol | Cardilol | Cardipres | Carvedil | Carvedilol sandoz | Carveta xr | Carvibloc | Carvid | Carvida | Carvidol | Dilabloc | Dilatrend | Duobloc | Glovedol | Karvidol | Karvil | Psicardiol | Ritemed carvedilol | Vasolexin | Vedilcard | Xicard</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Cardiset | Carevol | Carken | Carlov | Carpro | Carveda | Carvid | Carvilol | Coregen | Corubin | Dimitone | Hart | Hidilol | Karvic | Natilol | Otello | Vedicar | Vedigit | Vedilol</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Atram | Avedol | Carvedigamma | Carvedilol genoptim | Carvedilol orion | Carvedilol Pfizer | Carvedilol ratiopharm | Carvedilol teva | Carvilex | Carvin | Coryol | Dilatrend | Hypoten | Mavodilol | Symtrend | Vivacor</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Carvedilol phosphate | Coreg</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Blocan | Carvedilol aurbindo | Carvedilol Azevedos | Carvedilol basi | Carvedilol generis | Carvedilol germed | Carvedilol mylan | Carvedilol parke davis | Carvedilol ratiopharm | Carvedilol ritisca | Carvedilol Tecnimede | Coronat | Dilbloc | Dilbloc ic | Kredex</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Betaril | Blotenol | Cardicap | Cardiodil | Carvebol | Carvedil | Carvedilol dallas | Carvedilol polimed | Carvedilol sandoz | Carvedilol vivele | Corozem | Curpinol | Dilatrend | Dualten | Filten | Isobloc | Lodipres | Madrix | Madrix xr | Monocardil | Vecar | Xetin | Ziclar</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Dilatrend</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Atram | Carvedigamma | Carvedilol aurobindo | Carvedilol lph | Carvedilol sandoz | Carvedilol vim spectrum | Coryol | Dilatrend | Gladycor | Talliton</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Acridilol | Atram | Bagodilol | Cardivas | Carvedigamma | Carvedilol akrikhin | Carvedilol canon | Carvedilol sandoz | Carvedilol stada | Carvedilol teva | Carvedilol zentiva | Carvediol | Carvenal | Carvetrend | Carvidil | Coriol | Coryol | Dilatrend | Recardium | Talliton | Vedicardol | Velcardio</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo carvedilol | Carlol v | Dilatrend | Pms-carvedilol | Ravildo</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Carvedilol 2care4 | Carvedilol Alpharma | Carvedilol alternova | Carvedilol aurobindo | Carvedilol ebb | Carvedilol EQL Pharma | Carvedilol hexal | Carvedilol Orifarm | Carvedilol orion pharma | Carvedilol ratiopharm | Carvedilol sandoz | Carvedilol stada | Carvedilol teva | Carveratio | Karvedilol Actavis | Kredex</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Carvepen | Dilatrend | Vacodil</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Carvedigamma | Coryol | Dilatrend</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Carvedigamma | Carvedilol orion | Carvedilol teva | Coryol | Dilatrend | Ocarox | Talliton</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Caraten | Dilatrend | Tocarlol</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Cardilol | Carvidol | Karvex</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Arlec | Calbicor | Carvesan | Carvexal | Coronis | Dilatrend | Kinetra</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cardilo | Carlatrend | Carvedil | Carvedilol hexal | Carvedilol teva | Carvo | Dilatrend | Longcardio | Pinvio | Syntrend | Udilol | Yesindon</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Atram | Cardilol | Cardiostad | Cardivas | Carvedigamma | Carvedilol aurobindo | Carvedilol zentiva | Carvidex | Corvasan | Coryol | Dilator | Karvium | Medocardil | Protecard | Talliton</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Avernol | Cardoz | Carvedi denk | Carvetas | Carviberg | Carvil</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Bidecar | Cardiodil | Carvedil | Carvemox | Dilatrend | Tensibona</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cardibiol | Cardivas | Carvedil | Carvel | Carvidex | Coventrol | Dilatrend | Psicardiol | Trelol</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Aucardil | Carsantin | Carvesyl | Peruzi | Suncardivas | Vedicard</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aspen-carvedilol | Carloc | Carvedilol hexal | Carvedilol oethmaan | Carvedilol Unicorn | Dilatrend | Rubitrend | Vediblok</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Carvetrend | Karvil | Normidilol</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Carca | Karvil</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29097320">
<a name="29097320"></a>Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Heart Rhythm</i>. 2018;15(10):e190-e252. doi:10.1016/j.hrthm.2017.10.035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/29097320/pubmed" id="29097320" target="_blank">29097320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575676">
<a name="30575676"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 203: Chronic hypertension in pregnancy. <i>Obstet Gynecol</i>. 2019;133(1):e26-e50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/30575676/pubmed" id="30575676" target="_blank">30575676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25260718">
<a name="25260718"></a>Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi:10.1016/j.jacc.2014.09.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/25260718/pubmed" id="25260718" target="_blank">25260718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21518977">
<a name="21518977"></a>Aronow WS, Fleg JL, Pepine CJ, et al; ACCF Task Force. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. <i>Circulation</i>. 2011;123(21):2434-2506. doi:10.1161/CIR.0b013e31821daaf6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/21518977/pubmed" id="21518977" target="_blank">21518977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15536109">
<a name="15536109"></a>Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. <i>JAMA</i>. 2004;292(18):2227-2236. doi:10.1001/jama.292.18.2227<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/15536109/pubmed" id="15536109" target="_blank">15536109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12447861">
<a name="12447861"></a>Bañares R, Moitinho E, Matilla A, et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. <i>Hepatology</i>. 2002;36(6):1367-1373. doi:10.1053/jhep.2002.36947<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/12447861/pubmed" id="12447861" target="_blank">12447861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23796325">
<a name="23796325"></a>Barron AJ, Zaman N, Cole GD, Wensel R, Okonko DO, Francis DP. Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information. <i>Int J Cardiol</i>. 2013;168(4):3572-3579. doi:10.1016/j.ijcard.2013.05.068<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/23796325/pubmed" id="23796325" target="_blank">23796325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27298379">
<a name="27298379"></a>Bhardwaj A, Kedarisetty CK, Vashishtha C, et al. Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial. <i>Gut</i>. 2017;66(10):1838-1843. doi:10.1136/gutjnl-2016-311735<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/27298379/pubmed" id="27298379" target="_blank">27298379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33942342">
<a name="33942342"></a>Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2021;74(2):1014-1048. doi:10.1002/hep.31884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/33942342/pubmed" id="33942342" target="_blank">33942342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Botros.1">
<a name="Botros.1"></a>Botros SM, Hussein AM, Elserafy AS. Effect of different beta blockers on penile vascular velocities in hypertensive males. <i>The Egyptian Journal of Radiology and Nuclear Medicine</i>. 2015;46(3):749-754. doi:10.1016/j.ejrnm.2015.04.004</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11295713">
<a name="11295713"></a>Bruns LA, Chrisant MK, Lamour JM, et al. Carvedilol as Therapy in Pediatric Heart Failure: An Initial Multicenter Experience. <i>J Pediatr</i>. 2001;138(4):505-511.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/11295713/pubmed" id="11295713" target="_blank">11295713</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29746858">
<a name="29746858"></a>Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. <i>J Urol</i>. 2018;200(3):633-641. doi:10.1016/j.juro.2018.05.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/29746858/pubmed" id="29746858" target="_blank">29746858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31841131">
<a name="31841131"></a>Cífková R, Johnson MR, Kahan T, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. <i>Eur Heart J Cardiovasc Pharmacother</i>. 2020;6(6):384-393. doi:10.1093/ehjcvp/pvz082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/31841131/pubmed" id="31841131" target="_blank">31841131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Coreg.2">
<a name="Coreg.2"></a>Coreg (carvedilol) [prescribing information]. Wixom, MI: Woodward Pharma Services; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Coreg.2">
<a name="Coreg.2"></a>Coreg (carvedilol) tablet [prescribing information]. Wixom, MI: Woodward Pharma Services; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Coreg.1">
<a name="Coreg.1"></a>Coreg (carvedilol immediate release) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; September 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CoregCR.1">
<a name="CoregCR.1"></a>Coreg CR (carvedilol extended release) [prescribing information]. Wixom, MI: Woodward Pharma Services LLC; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15579370">
<a name="15579370"></a>Covar RA, Macomber BA, Szefler SJ. Medications as asthma triggers. <i>Immunol Allergy Clin North Am</i>. 2005;25(1):169-190. doi:10.1016/j.iac.2004.09.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/15579370/pubmed" id="15579370" target="_blank">15579370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3009050">
<a name="3009050"></a>Croft CH, Rude RE, Gustafson N, et al. Abrupt withdrawal of beta-blockade therapy in patients with myocardial infarction: effects on infarct size, left ventricular function, and hospital course. <i>Circulation</i>. 1986;73(6):1281-1290. doi:10.1161/01.cir.73.6.1281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/3009050/pubmed" id="3009050" target="_blank">3009050</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1969714">
<a name="1969714"></a>Dahlöf C, Dimenäs E. Side effects of beta-blocker treatments as related to the central nervous system. <i>Am J Med Sci</i>. 1990;299(4):236-244. doi:10.1097/00000441-199004000-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/1969714/pubmed" id="1969714" target="_blank">1969714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11356434">
<a name="11356434"></a>Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. <i>Lancet</i>. 2001;357(9266):1385-1390.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/11356434/pubmed" id="11356434" target="_blank">11356434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31775749">
<a name="31775749"></a>Dungan K, Merrill J, Long C, Binkley P. Effect of beta blocker use and type on hypoglycemia risk among hospitalized insulin requiring patients. <i>Cardiovasc Diabetol</i>. 2019;18(1):163. doi:10.1186/s12933-019-0967-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/31775749/pubmed" id="31775749" target="_blank">31775749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2897781">
<a name="2897781"></a>Egstrup K. Transient myocardial ischemia after abrupt withdrawal of antianginal therapy in chronic stable angina. <i>Am J Cardiol</i>. 1988;61(15):1219-1222. doi:10.1016/0002-9149(88)91158-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/2897781/pubmed" id="2897781" target="_blank">2897781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33945044">
<a name="33945044"></a>Farmakis IT, Pyrgidis N, Doundoulakis I, Mykoniatis I, Akrivos E, Giannakoulas G. Effects of major antihypertensive drug classes on erectile function: a network meta-analysis. <i>Cardiovasc Drugs Ther</i>. 2022;36(5):903-914. doi:10.1007/s10557-021-07197-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/33945044/pubmed" id="33945044" target="_blank">33945044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23166211">
<a name="23166211"></a>Fihn SD, Gardin JM, Abrams J, et al; American College of Cardiology Foundation/American Heart Association Task Force. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. <i>Circulation</i>. 2012;126(25):e354-e471. doi:10.1161/CIR.0b013e318277d6a0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/23166211/pubmed" id="23166211" target="_blank">23166211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11206674">
<a name="11206674"></a>Fogari R, Zoppi A, Poletti L, Marasi G, Mugellini A, Corradi L. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. <i>Am J Hypertens</i>. 2001;14(1):27-31. doi:10.1016/s0895-7061(00)01214-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/11206674/pubmed" id="11206674" target="_blank">11206674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18617067">
<a name="18617067"></a>Fonarow GC, Abraham WT, Albert NM, et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. <i>J Am Coll Cardiol</i>. 2008;52(3):190-199. doi:10.1016/j.jacc.2008.03.048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/18617067/pubmed" id="18617067" target="_blank">18617067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20067434">
<a name="20067434"></a>Fonseca VA. Effects of beta-blockers on glucose and lipid metabolism. <i>Curr Med Res Opin</i>. 2010;26(3):615-629. doi:10.1185/03007990903533681<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/20067434/pubmed" id="20067434" target="_blank">20067434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6867180">
<a name="6867180"></a>Foster CA, Aston SJ. Propranolol-Epinephrine Interaction: A Potential Disaster. <i>Plast Reconstr Surg</i>. 1983;72(1):74-78.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/6867180/pubmed" id="6867180" target="_blank">6867180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2883874">
<a name="2883874"></a>Frishman WH. Beta-adrenergic blocker withdrawal. <i>Am J Cardiol</i>. 1987;59(13):26F-32F. doi:10.1016/0002-9149(87)90038-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/2883874/pubmed" id="2883874" target="_blank">2883874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2892986">
<a name="2892986"></a>Frishman WH. Beta-adrenergic blockers. <i>Med Clin North Am</i>. 1988;72(1):37-81. doi:10.1016/s0025-7125(16)30786-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/2892986/pubmed" id="2892986" target="_blank">2892986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi:10.1210/jc.2015-4061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27786365">
<a name="27786365"></a>Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2017;65(1):310-335. doi:10.1002/hep.28906<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/27786365/pubmed" id="27786365" target="_blank">27786365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10424319">
<a name="10424319"></a>Gehr TW, Tenero DM, Boyle DA, Qian Y, Sica DA, Shusterman NH. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. <i>Eur J Clin Pharmacol</i>. 1999;55(4):269-277. doi:10.1007/s002280050628<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/10424319/pubmed" id="10424319" target="_blank">10424319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8956349">
<a name="8956349"></a>Gleiter CH, Deckert J. Adverse CNS-effects of beta-adrenoceptor blockers. <i>Pharmacopsychiatry</i>. 1996;29(6):201-211. doi:10.1055/s-2007-979572<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/8956349/pubmed" id="8956349" target="_blank">8956349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17534003">
<a name="17534003"></a>Gliebus G, Lippa CF. The influence of beta-blockers on delayed memory function in people with cognitive impairment. <i>Am J Alzheimers Dis Other Demen</i>. 2007;22(1):57-61. doi:10.1177/1533317506295889<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/17534003/pubmed" id="17534003" target="_blank">17534003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24243703">
<a name="24243703"></a>Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. <i>Hypertension</i>. Published online November 15, 2013.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/24243703/pubmed" id="24243703" target="_blank">24243703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11724083">
<a name="11724083"></a>Hagmeyer KO, Stein J. Hepatotoxicity associated with carvedilol. <i>Ann Pharmacother</i>. 2001;35(11):1364-1366. doi:10.1345/aph.10239<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/11724083/pubmed" id="11724083" target="_blank">11724083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1244260">
<a name="1244260"></a>Harrison DC, Alderman EL. Editorial: Discontinuation of propranolol therapy. Cause of rebound angina pectoris and acute coronary events. <i>Chest</i>. 1976;69(1):1-2. doi:10.1378/chest.69.1.1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/1244260/pubmed" id="1244260" target="_blank">1244260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9174677">
<a name="9174677"></a>Hauf-Zachariou U, Blackwood RA, Gunawardena KA, O'Donnell JG, Garnham S, Pfarr E. Carvedilol versus verapamil in chronic stable angina: a multicentre trial. <i>Eur J Clin Pharmacol</i>. 1997;52(2):95-100. doi:10.1007/s002280050256<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/9174677/pubmed" id="9174677" target="_blank">9174677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23108482">
<a name="23108482"></a>Huang M, Zhang X, Chen S, et al. The effect of carvedilol treatment on chronic heart failure in pediatric patients with dilated cardiomyopathy: a prospective, randomized-controlled study. <i>Pediatr Cardiol</i>. 2013;34(3):680-685. doi:10.1007/s00246-012-0527-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/23108482/pubmed" id="23108482" target="_blank">23108482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1977302">
<a name="1977302"></a>Jaillon P. Relevance of intrinsic sympathomimetic activity for beta blockers. <i>Am J Cardiol</i>. 1990;66(9):21C-23C. doi:10.1016/0002-9149(90)90758-s<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/1977302/pubmed" id="1977302" target="_blank">1977302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24352797">
<a name="24352797"></a>James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. 2014;311(5):507-520.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/24352797/pubmed" id="24352797" target="_blank">24352797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-JAMPCarvedilol.1">
<a name="JAMPCarvedilol.1"></a>JAMP-Carvedilol [product monograph]. Boucherville, Quebec, Canada: JAMP Pharma Corporation; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24682347">
<a name="24682347"></a>January CT, Wann LS, Alpert JS, et al; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published correction appears in <i>Circulation</i>. 2014;130(23):e272-e274]. <i>Circulation</i>. 2014;130(23):e199-e267. doi:10.1161/CIR.0000000000000041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/24682347/pubmed" id="24682347" target="_blank">24682347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30703530">
<a name="30703530"></a>January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Heart Rhythm</i>. 2019. pii: S1547-5271(19)30037-2. doi:10.1016/j.hrthm.2019.01.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/30703530/pubmed" id="30703530" target="_blank">30703530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16793810">
<a name="16793810"></a>Juul AB, Wetterslev J, Gluud C, et al. Effect of Perioperative Beta-Blockade in Patients With Diabetes Undergoing Major Non-Cardiac Surgery: Randomized Placebo Controlled, Blinded Multicentre Trial. <i>BMJ</i>. 2006;332(7556):1482.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/16793810/pubmed" id="16793810" target="_blank">16793810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kannam.1">
<a name="Kannam.1"></a>Kannam JP, Gersh BJ. Beta blockers in the management of chronic coronary syndrome. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 21, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14662257">
<a name="14662257"></a>Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? <i>J Am Coll Cardiol</i>. 2003;42(11):1944-1951.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/14662257/pubmed" id="14662257" target="_blank">14662257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12117400">
<a name="12117400"></a>Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. <i>JAMA</i>. 2002;288(3):351-357. doi:10.1001/jama.288.3.351<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/12117400/pubmed" id="12117400" target="_blank">12117400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2865151">
<a name="2865151"></a>Koella WP. CNS-related (side-)effects of beta-blockers with special reference to mechanisms of action. <i>Eur J Clin Pharmacol</i>. 1985;28(suppl):55-63. doi:10.1007/BF00543711<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/2865151/pubmed" id="2865151" target="_blank">2865151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2878741">
<a name="2878741"></a>Kostis JB, Rosen RC. Central nervous system effects of beta-adrenergic-blocking drugs: the role of ancillary properties. <i>Circulation</i>. 1987;75(1):204-212. doi:10.1161/01.cir.75.1.204<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/2878741/pubmed" id="2878741" target="_blank">2878741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12490274">
<a name="12490274"></a>Kotlyar E, Keogh AM, Macdonald PS, Arnold RH, McCaffrey DJ, Glanville AR. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. <i>J Heart Lung Transplant</i>. 2002;21(12):1290-1295. doi:10.1016/s1053-2498(02)00459-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/12490274/pubmed" id="12490274" target="_blank">12490274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9295009">
<a name="9295009"></a>Kowalski BJ, Cody RJ. Stevens-Johnson syndrome associated with carvedilol therapy. <i>Am J Cardiol</i>. 1997;80(5):669-670. doi:10.1016/s0002-9149(97)00449-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/9295009/pubmed" id="9295009" target="_blank">9295009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1505616">
<a name="1505616"></a>Krämer BK, Ress KM, Erley CM, Risler T. Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure. <i>Eur J Clin Pharmacol</i>. 1992;43(1):85-88. doi:10.1007/BF02280760<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/1505616/pubmed" id="1505616" target="_blank">1505616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12040358">
<a name="12040358"></a>Läer S, Mir TS, Behn F, et al. Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. <i>Am Heart J</i>. 2002;143(5):916-922. doi:10.1067/mhj.2002.121265<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/12040358/pubmed" id="12040358" target="_blank">12040358</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-85053">
<a name="85053"></a>Lager I, Blohmé G, Smith U. Effect of cardioselective and non-selective beta-blockade on the hypoglycaemic response in insulin-dependent diabetics. <i>Lancet</i>. 1979;1(8114):458-462. doi:10.1016/s0140-6736(79)90821-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/85053/pubmed" id="85053" target="_blank">85053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2439802">
<a name="2439802"></a>Lammers JW, Folgering HT, van Herwaarden CL. Respiratory tolerance of bisoprolol and metoprolol in asthmatic patients. <i>J Cardiovasc Pharmacol</i>. 1986;8 suppl 11:S69-S73. doi:10.1097/00005344-198511001-00012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/2439802/pubmed" id="2439802" target="_blank">2439802</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37093">
<a name="37093"></a>Lederballe Pedersen O, Mikkelsen E, Lanng Nielsen J, Christensen NJ. Abrupt withdrawal of beta-blocking agents in patients with arterial hypertension. Effect on blood pressure, heart rate and plasma catecholamines and prolactin. <i>Eur J Clin Pharmacol</i>. 1979;15(3):215-217. doi:10.1007/BF00563108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/37093/pubmed" id="37093" target="_blank">37093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19198819">
<a name="19198819"></a>Lennestål R, Otterblad Olausson P, Källén B. Maternal Use of Antihypertensive Drugs in Early Pregnancy and Delivery Outcome, Notably the Presence of Congenital Heart Defects in the Infants. <i>Eur J Clin Pharmacol</i>. 2009;65(6):615-625.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/19198819/pubmed" id="19198819" target="_blank">19198819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22267844">
<a name="22267844"></a>Levine GN, Steinke EE, Bakaeen FG, et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Quality of Care and Outcomes Research. Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. <i>Circulation</i>. 2012;125(8):1058-1072. doi:10.1161/CIR.0b013e3182447787<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/22267844/pubmed" id="22267844" target="_blank">22267844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27390282">
<a name="27390282"></a>Lipworth B, Wedzicha J, Devereux G, Vestbo J, Dransfield MT. Beta-blockers in COPD: time for reappraisal. <i>Eur Respir J</i>. 2016;48(3):880-888. doi:10.1183/13993003.01847-2015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/27390282/pubmed" id="27390282" target="_blank">27390282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15288162">
<a name="15288162"></a>López-Sendón J, Swedberg K, McMurray J, et al. Expert consensus document on beta-adrenergic receptor blockers. <i>Eur Heart J</i>. 2004;25(15):1341-1362. doi:10.1016/j.ehj.2004.06.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/15288162/pubmed" id="15288162" target="_blank">15288162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27899939">
<a name="27899939"></a>Lu HT, Kam J, Nordin RB, et al. Beta-blocker use and risk of symptomatic bradyarrhythmias: a hospital-based case-control study. <i>J Geriatr Cardiol</i>. 2016;13(9):749-759. doi:10.11909/j.issn.1671-5411.2016.09.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/27899939/pubmed" id="27899939" target="_blank">27899939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35577426">
<a name="35577426"></a>Magee LA, Smith GN, Bloch C, et al. Guideline no. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. <i>J Obstet Gynaecol Can</i>. 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/35577426/pubmed" id="35577426" target="_blank">35577426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1378134">
<a name="1378134"></a>Masumura H, Miki S, Kaifu Y, Kitajima W, Abe Y. Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients. <i>J Cardiovasc Pharmacol</i>. 1992;19(suppl 1):S102-S107. doi:10.1097/00005344-199219001-00020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/1378134/pubmed" id="1378134" target="_blank">1378134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1969642">
<a name="1969642"></a>McAinsh J, Cruickshank JM. Beta-blockers and central nervous system side effects. <i>Pharmacol Ther</i>. 1990;46(2):163-197. doi:10.1016/0163-7258(90)90092-g<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/1969642/pubmed" id="1969642" target="_blank">1969642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7681374">
<a name="7681374"></a>McTavish D, Campoli-Richards D, Sorkin EM. Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. <i>Drugs</i>. 1993;45(2):232-258. doi:10.2165/00003495-199345020-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/7681374/pubmed" id="7681374" target="_blank">7681374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1721982">
<a name="1721982"></a>Miki S, Masumura H, Kaifu Y, Yuasa S. Pharmacokinetics and efficacy of carvedilol in chronic hemodialysis patients with hypertension. <i>J Cardiovasc Pharmacol</i>. 1991;18(suppl 4):S62-S68.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/1721982/pubmed" id="1721982" target="_blank">1721982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2861072">
<a name="2861072"></a>Mills GA, Horn JR. Beta-blockers and glucose control. <i>Drug Intell Clin Pharm</i>. 1985;19(4):246-251. doi:10.1177/106002808501900401<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/2861072/pubmed" id="2861072" target="_blank">2861072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). NICE guideline: hypertension in pregnancy: diagnosis and management. http://www.nice.org.uk/guidance/ng133/. Updated June 25, 2019. Accessed December 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nemecek.1">
<a name="Nemecek.1"></a>Nemecek BD, Hammond DA, eds. <i>Demystifying drug dosing in renal dysfunction</i>. American Society of Health-System Pharmacists; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956224">
<a name="20956224"></a>Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care [published corrections appear in <i>Circulation</i>. 2011;123(6):e236; <i>Circulation</i>. 2013;128(25):e480]. <i>Circulation</i>. 2010;122(18)(suppl 3):S729-S767. doi:10.1161/CIRCULATIONAHA.110.970988<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/20956224/pubmed" id="20956224" target="_blank">20956224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24155101">
<a name="24155101"></a>Nicolai MP, Liem SS, Both S, et al. A review of the positive and negative effects of cardiovascular drugs on sexual function: a proposed table for use in clinical practice. <i>Neth Heart J</i>. 2014;22(1):11-19. doi:10.1007/s12471-013-0482-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/24155101/pubmed" id="24155101" target="_blank">24155101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29766868">
<a name="29766868"></a>Nikolaidou T, Ghosh JM, Clark AL. Outcomes related to first-degree atrioventricular block and therapeutic implications in patients with heart failure. <i>JACC Clin Electrophysiol</i>. 2016;2(2):181-192. doi:10.1016/j.jacep.2016.02.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/29766868/pubmed" id="29766868" target="_blank">29766868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24589852">
<a name="24589852"></a>Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-2492. doi:10.1161/CIR.0000000000000029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/24589852/pubmed" id="24589852" target="_blank">24589852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23247304">
<a name="23247304"></a>O'Gara PT, Kushner FG, Ascheim DD, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481]. <i>Circulation</i>. 2013;127(4):e362-e425. doi:10.1161/CIR.0b013e3182742cf6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/23247304/pubmed" id="23247304" target="_blank">23247304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22530749">
<a name="22530749"></a>Osmonov D, Erdinler I, Ozcan KS, et al. Management of patients with drug-induced atrioventricular block. <i>Pacing Clin Electrophysiol</i>. 2012;35(7):804-810. doi:10.1111/j.1540-8159.2012.03410.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/22530749/pubmed" id="22530749" target="_blank">22530749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8614419">
<a name="8614419"></a>Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.<i> N Engl J Med</i>. 1996;334(21):1349-1355. doi:10.1056/NEJM199605233342101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/8614419/pubmed" id="8614419" target="_blank">8614419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11386263">
<a name="11386263"></a>Packer M, Coats AJ, Fowler MB, et al; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. <i>N Engl J Med.</i> 2001;344(22):1651-1658. doi:10.1056/NEJM200105313442201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/11386263/pubmed" id="11386263" target="_blank">11386263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33081529">
<a name="33081529"></a>Panchal AR, Bartos JA, Cabañas JG, et al; Adult Basic and Advanced Life Support Writing Group. Part 3: adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2020;142(16)(suppl 2):S366-S468. doi:10.1161/CIR.0000000000000916<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/33081529/pubmed" id="33081529" target="_blank">33081529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6344309">
<a name="6344309"></a>Patakas D, Argiropoulou V, Louridas G, Tsara V. Beta-blockers in bronchial asthma: effect of propranolol and pindolol on large and small airways. <i>Thorax</i>. 1983;38(2):108-112. doi:10.1136/thx.38.2.108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/6344309/pubmed" id="6344309" target="_blank">6344309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6376017">
<a name="6376017"></a>Popp DA, Tse TF, Shah SD, Clutter WE, Cryer PE. Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus. <i>Diabetes Care</i>. 1984;7(3):243-247. doi:10.2337/diacare.7.3.243<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/6376017/pubmed" id="6376017" target="_blank">6376017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6125186">
<a name="6125186"></a>Prichard BN, Walden RJ. The syndrome associated with the withdrawal of beta-adrenergic receptor blocking drugs. <i>Br J Clin Pharmacol</i>. 1982;13(Suppl 2):337S-343S. doi:10.1111/j.1365-2125.1982.tb01938.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/6125186/pubmed" id="6125186" target="_blank">6125186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2897302">
<a name="2897302"></a>Proclemer A, Gradnik R, Savonitto S, Feruglio GA. Electrophysiological effects of bisoprolol. <i>Eur Heart J.</i> 1987;8(Suppl M):81-85. doi:10.1093/eurheartj/8.suppl_m.81<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/2897302/pubmed" id="2897302" target="_blank">2897302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2450898">
<a name="2450898"></a>Prystowsky EN. The effects of slow channel blockers and beta blockers on atrioventricular nodal conduction. <i>J Clin Pharmacol</i>. 1988;28(1):6-21. doi:10.1002/j.1552-4604.1988.tb03095.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/2450898/pubmed" id="2450898" target="_blank">2450898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1968518">
<a name="1968518"></a>Psaty BM, Koepsell TD, Wagner EH, LoGerfo JP, Inui TS. The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. <i>JAMA</i>. 1990;263(12):1653-1657.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/1968518/pubmed" id="1968518" target="_blank">1968518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26995368">
<a name="26995368"></a>Ranchord AM, Spertus JA, Buchanan DM, Gosch KL, Chan PS. Initiation of β-blocker therapy and depression after acute myocardial infarction. <i>Am Heart J</i>. 2016;174:37-42. doi:10.1016/j.ahj.2015.11.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/26995368/pubmed" id="26995368" target="_blank">26995368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6125187">
<a name="6125187"></a>Rangno RE, Langlois S. Comparison of withdrawal phenomena after propranolol, metoprolol and pindolol. <i>Br J Clin Pharmacol</i>. 1982;13(Suppl 2):345S-351S. doi:10.1111/j.1365-2125.1982.tb01939.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/6125187/pubmed" id="6125187" target="_blank">6125187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16210252">
<a name="16210252"></a>Redelmeier D, Scales D, and Kopp A, "Beta Blockers for Elective Surgery in Elderly Patients: Population Based, Retrospective Cohort Study," <i>BMJ</i>, 2005, 331(7522):932.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/16210252/pubmed" id="16210252" target="_blank">16210252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23250049">
<a name="23250049"></a>Reiberger T, Ulbrich G, Ferlitsch A, et al; Vienna Hepatic Hemodynamic Lab. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. <i>Gut</i>. 2013;62(11):1634-1641. doi:10.1136/gutjnl-2012-304038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/23250049/pubmed" id="23250049" target="_blank">23250049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19724774">
<a name="19724774"></a>Rogers D, Pies R. General medical with depression drugs associated. <i>Psychiatry (Edgmont)</i>. 2008;5(12):28-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/19724774/pubmed" id="19724774" target="_blank">19724774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31192288">
<a name="31192288"></a>Rua J, Prata AR, Marques R, et al. Carvedilol-induced liver injury, a rare cause of mixed hepatitis: a clinical case. <i>GE Port J Gastroenterol</i>. 2019;26(3):196-201. doi:10.1159/000490205<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/31192288/pubmed" id="31192288" target="_blank">31192288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15261177">
<a name="15261177"></a>Rusconi P, Gomez-Marin O, Rossique-Gonzalez M, et al. Carvedilol in Children With Cardiomyopathy: 3-Year Experience at a Single Institution. <i>J Heart Lung Transplant</i>. 2004;23(7):832-838.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/15261177/pubmed" id="15261177" target="_blank">15261177</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sanyal.2019">
<a name="Sanyal.2019"></a>Sanyal AJ, Garcia-Pagán JC. Primary prevention of bleeding from esophageal varices in patients with cirrhosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 29, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23024438">
<a name="23024438"></a>Scheer FA, Morris CJ, Garcia JI, et al. Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial. <i>Sleep</i>. 2012;35(10):1395-1402. doi:10.5665/sleep.2122<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/23024438/pubmed" id="23024438" target="_blank">23024438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28622464">
<a name="28622464"></a>Semet M, Paci M, Saïas-Magnan J, et al. The impact of drugs on male fertility: a review. <i>Andrology</i>. 2017;5(4):640-663. doi:10.1111/andr.12366<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/28622464/pubmed" id="28622464" target="_blank">28622464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17848651">
<a name="17848651"></a>Shaddy RE, Boucek MM, Hsu DT, et al. Carvedilol for Children and Adolescents With Heart Failure: A Randomized Controlled Trial. <i>JAMA</i>. 2007;298(10):1171-1179.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/17848651/pubmed" id="17848651" target="_blank">17848651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-668066">
<a name="668066"></a>Shand DG, Wood AJ. Propranolol withdrawal syndrome - why? <i>Circulation</i>. 1978;58(2):202-203. doi:10.1161/01.cir.58.2.202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/668066/pubmed" id="668066" target="_blank">668066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34331033">
<a name="34331033"></a>Terentes-Printzios D, Ioakeimidis N, Rokkas K, Vlachopoulos C. Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs. <i>Nat Rev Cardiol</i>. 2022;19(1):59-74. doi:10.1038/s41569-021-00593-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/34331033/pubmed" id="34331033" target="_blank">34331033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19610055">
<a name="19610055"></a>Tripathi D, Ferguson JW, Kochar N, et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. <i>Hepatology</i>. 2009;50(3):825-833. doi:10.1002/hep.23045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/19610055/pubmed" id="19610055" target="_blank">19610055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28559400">
<a name="28559400"></a>Tsujimoto T, Sugiyama T, Shapiro MF, Noda M, Kajio H. Risk of cardiovascular events in patients with diabetes mellitus on β-blockers. <i>Hypertension</i>. 2017;70(1):103-110. doi:10.1161/HYPERTENSIONAHA.117.09259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/28559400/pubmed" id="28559400" target="_blank">28559400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32073535">
<a name="32073535"></a>Viigimaa M, Vlachopoulos C, Doumas M, et al; European Society of Hypertension Working Group on Sexual Dysfunction. Update of the position paper on arterial hypertension and erectile dysfunction. <i>J Hypertens</i>. 2020;38(7):1220-1234. doi:10.1097/HJH.0000000000002382<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/32073535/pubmed" id="32073535" target="_blank">32073535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20650047">
<a name="20650047"></a>Vlahovic-Palcevski V, Milic S, Hauser G, et al. Toxic epidermal necrolysis associated with carvedilol treatment. <i>Int J Clin Pharmacol Ther</i>. 2010;48(8):549-551. doi:10.5414/cpp48549<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/20650047/pubmed" id="20650047" target="_blank">20650047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vue.1">
<a name="Vue.1"></a>Vue MH, Setter SM. Drug-induced glucose alterations part 1: drug-induced hypoglycemia. <i>Diabetes Spectrum</i>. 2011;24(3):171-177. doi:10.2337/diaspect.24.3.171</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20579773">
<a name="20579773"></a>Wang J, Ono K, Dickstein DL, et al. Carvedilol as a potential novel agent for the treatment of Alzheimer's disease. <i>Neurobiol Aging</i>. 2011;32(12):2321.e1-2321.e23212. doi:10.1016/j.neurobiolaging.2010.05.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/20579773/pubmed" id="20579773" target="_blank">20579773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24341872">
<a name="24341872"></a>Weber MA, Schiffrin EL, White WB, et al, Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/24341872/pubmed" id="24341872" target="_blank">24341872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9794346">
<a name="9794346"></a>Weiss R, Ferry D, Pickering E, et al. Effectiveness of three different doses of carvedilol for exertional angina. Carvedilol-Angina Study Group. <i>Am J Cardiol</i>. 1998;82(8):927-931. doi:10.1016/s0002-9149(98)00507-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/9794346/pubmed" id="9794346" target="_blank">9794346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2865153">
<a name="2865153"></a>Westerlund A. Central nervous system side-effects with hydrophilic and lipophilic beta-blockers. <i>Eur J Clin Pharmacol</i>. 1985;28(suppl):73-76. doi:10.1007/BF00543714<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/2865153/pubmed" id="2865153" target="_blank">2865153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133356">
<a name="29133356"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in <i>Hypertension</i>. 2018;71(6):e140-e144]. <i>Hypertension</i>. 2018;71(6):e13-e115. doi:10.1161/HYP.0000000000000065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/29133356/pubmed" id="29133356" target="_blank">29133356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7911769">
<a name="7911769"></a>Wynn RL. Epinephrine Interactions With Beta-Blockers. <i>Gen Dent</i>. 1994;42(1):16, 18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/7911769/pubmed" id="7911769" target="_blank">7911769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15234417">
<a name="15234417"></a>Zeltser D, Justo D, Halkin A, et al. Drug-induced atrioventricular block: prognosis after discontinuation of the culprit drug. <i>J Am Coll Cardiol</i>. 2004;44(1):105-108. doi:10.1016/j.jacc.2004.03.057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carvedilol-pediatric-drug-information/abstract-text/15234417/pubmed" id="15234417" target="_blank">15234417</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12921 Version 617.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
